Supernus Pharmaceuticals to Showcase Q2 Financial Outcomes
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a leading biopharmaceutical firm, is preparing to announce its financial and operational results for the second quarter of 2025. Investors and stakeholders can expect the report to be available after market hours on an upcoming Tuesday, with a date soon approaching.
Accessing the Conference Call
On the day of the announcement, Jack Khattar, the President and CEO of Supernus, along with Tim Dec, the Senior Vice President and CFO, will guide a comprehensive conference call. This session is scheduled to take place at 4:30 PM ET, where management will share both financial and business developments while also fielding questions from participants.
Participating in the Call
Investors wishing to engage in the discussion can pre-register through the company’s Investor Relations portal. Post-registration will provide the necessary dial-in details and a personal conference code. It's advisable for participants to join the call a quarter of an hour prior to its commencement to ensure a smooth experience.
Post-Call Replay Availability
For those unable to attend live, a replay of the call will be accessible on the Investor Relations section of Supernus’ website for a period of 60 days following the event. This service ensures that all interested parties can stay updated on the company's progress and insights shared during the call.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals is dedicated to creating and commercializing innovative products specifically aimed at treating central nervous system (CNS) diseases. The company boasts a diverse portfolio focusing on conditions such as attention-deficit hyperactivity disorder (ADHD), migraine, epilepsy, and Parkinson’s disease, among others.
Focus on CNS Treatments
The company is not only expanding its existing product line but also actively developing a range of new candidate treatments that promise to address various CNS challenges. This initiative highlights Supernus's commitment to improving patient outcomes and enhancing the quality of life for individuals facing neurological disorders.
Investor Relations and Contact Information
For more details regarding financial updates and product developments, stakeholders are encouraged to visit Supernus’ official website. The site provides essential insights into the company’s ongoing projects, investor materials, and other essential updates.
Investor Contacts
Individuals looking to reach out regarding investment inquiries can contact:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Additionally, for further investor communication, connect with Peter Vozzo from ICR Healthcare at (443) 213-0505 or through email.
Frequently Asked Questions
1. What is Supernus Pharmaceuticals known for?
Supernus Pharmaceuticals is a biopharmaceutical company focusing on the treatment of central nervous system (CNS) diseases, developing innovative therapies for a range of conditions.
2. When will the Q2 2025 financial results be announced?
The financial results for the second quarter of 2025 are expected to be released after market close on an upcoming Tuesday.
3. Who will lead the conference call?
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will lead the conference call to discuss financial outcomes and answer questions.
4. Where can I access the webcast of the call?
A live webcast will be available in the Events & Presentations section of Supernus' Investor Relations website, and a replay will be accessible for 60 days after the call.
5. How can I contact Supernus Pharmaceuticals Investor Relations?
Investors can contact Jack A. Khattar or Peter Vozzo for inquiries regarding investment and clinical developments at the provided contact numbers.
